STOCK TITAN

[SCHEDULE 13G/A] BRISTOL MYERS SQUIBB CO SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

Bristol-Myers Squibb (BMY): Ownership update. JPMorgan Chase & Co. filed an amended Schedule 13G reporting beneficial ownership of 81,890,781 shares, representing 4.0% of BMY’s common stock as of 09/30/2025.

The filing lists 71,741,508 shares with sole voting power and 790,804 with shared voting power. It also reports 81,264,020 shares with sole dispositive power and 625,305 with shared dispositive power. JPMorgan certified the securities were acquired and are held in the ordinary course of business and not to change or influence control.

Bristol-Myers Squibb (BMY): Aggiornamento sull'ownership. JPMorgan Chase & Co. ha presentato un Schedule 13G corretto che riporta la titolarità benefica di 81.890.781 azioni, che rappresentano 4.0% del capitale sociale comune di BMY al 30/09/2025.

La comunicazione indica 71.741.508 azioni con potere di voto esclusivo e 790.804 con potere di voto condiviso. Rileva inoltre 81.264.020 azioni con potere dispositiva esclusivo e 625.305 con potere dispositiva condiviso. JPMorgan ha certificato che i titoli sono stati acquistati e detenuti nel normale svolgimento degli affari e non per modificare o influenzare il controllo.

Bristol-Myers Squibb (BMY): Actualización de la titularidad. JPMorgan Chase & Co. presentó un Schedule 13G enmendado reportando la titularidad beneficiosa de 81,890,781 acciones, que representan 4.0% de las acciones comunes de BMY al 30/09/2025.

El archivo señala 71,741,508 acciones con poder de voto exclusivo y 790,804 con poder de voto compartido. También informa 81,264,020 acciones con poder dispositivo exclusivo y 625,305 con poder dispositive compartido. JPMorgan certificó que los valores fueron adquiridos y se mantienen en el curso normal de los negocios y no para cambiar o influir en el control.

브리스톨-마이어스 스퀴브(BMY): 소유 현황 업데이트. JPMorgan Chase & Co.은 실질적 소유권 81,890,781주를 보고한 수정 Schedule 13G를 제출했으며, 이는 BMY의 보통주 4.0%에 해당합니다. 2025-09-30.

신고서는 단독 의결권이 있는 71,741,508주와 공동 의결권이 있는 790,804주를 목록에 올립니다. 또한 81,264,020주는 단독 처분 권한, 625,305주는 공동 처분 권한을 갖는 것으로 보고합니다. JPMorgan은 증권이 정상적인 영업상의 취득으로 이루어졌으며 지배권을 변경하거나 영향 주려는 목적이 아님을 증명했습니다.

Bristol-Myers Squibb (BMY) : Mise à jour de la propriété. JPMorgan Chase & Co. a déposé un Schedule 13G modifié annonçant une propriété bénéficiaire de 81 890 781 actions, représentant 4,0% des actions ordinaires de BMY au 30/09/2025.

Le dossier indique 71 741 508 actions avec pouvoir de vote exclusif et 790 804 avec pouvoir de vote partagé. Il indique également 81 264 020 actions avec pouvoir discrétionnaire exclusif et 625 305 avec pouvoir discrétionnaire partagé. JPMorgan a certifié que les titres ont été acquis et détenus dans le cadre normal des activités et non pour modifier ou influencer le contrôle.

Bristol-Myers Squibb (BMY): Eigentumsaktualisierung. JPMorgan Chase & Co. hat einen geänderten Schedule 13G eingereicht, der das wirtschaftliche Eigentum an 81.890.781 Aktien meldet, was 4,0% des BMY-Stammkapitals entspricht, zum 30.09.2025.

Die Einreichung listet 71.741.508 Aktien mit Alleinigem Stimmrecht und 790.804 mit gemeinsamem Stimmrecht. Sie meldet auch 81.264.020 Aktien mit Alleinem Verfügungsmacht und 625.305 mit gemeinsamer Verfügungsmacht. JPMorgan bestätigte, dass die Wertpapiere im normalen Geschäftsverlauf erworben und gehalten wurden und nicht dazu dienen, die Kontrolle zu ändern oder zu beeinflussen.

بريستل-مايرز سكويب (BMY): تحديث الملكية. قدمت جي بي مورجان تشيس وشركاه Schedule 13G معدلاً يفيد بالملكية المفيدة لـ81,890,781 سهماً، وهو يمثل 4.0% من أسهم BMY العادية حتى 30/09/2025.

تسرد الإيداع 71,741,508 سهماً بسلطة التصويت الحصرية و790,804 مع سلطة التصويت المشتركة. كما تقرر 81,264,020 سهماً بسلطة التصرف الحصري و625,305 مع سلطة التصرف المشتركة. وذكرت JPMorgan أن الأوراق المالية مكتسبة ومملوكة في إطار الأعمال الاعتيادية وليست بغرض تغيير أو التأثير في السيطرة.

Positive
  • None.
Negative
  • None.

Insights

Passive 13G/A shows JPMorgan at 4.0% of BMY.

JPMorgan reports a 4.0% beneficial stake in BMY (81,890,781 shares) as of 09/30/2025, filed on a Schedule 13G/A, the passive ownership form. The firm details sole vs. shared voting and dispositive powers, indicating typical institutional custody and advisory roles.

The certification states the position is held in the ordinary course and not for influencing control, aligning with 13G eligibility. The stake is below the 5% threshold referenced in the form, a level often associated with fewer heightened reporting triggers.

Actual market impact depends on portfolio and client decisions. Subsequent filings may update ownership levels if they change materially under applicable rules.

Bristol-Myers Squibb (BMY): Aggiornamento sull'ownership. JPMorgan Chase & Co. ha presentato un Schedule 13G corretto che riporta la titolarità benefica di 81.890.781 azioni, che rappresentano 4.0% del capitale sociale comune di BMY al 30/09/2025.

La comunicazione indica 71.741.508 azioni con potere di voto esclusivo e 790.804 con potere di voto condiviso. Rileva inoltre 81.264.020 azioni con potere dispositiva esclusivo e 625.305 con potere dispositiva condiviso. JPMorgan ha certificato che i titoli sono stati acquistati e detenuti nel normale svolgimento degli affari e non per modificare o influenzare il controllo.

Bristol-Myers Squibb (BMY): Actualización de la titularidad. JPMorgan Chase & Co. presentó un Schedule 13G enmendado reportando la titularidad beneficiosa de 81,890,781 acciones, que representan 4.0% de las acciones comunes de BMY al 30/09/2025.

El archivo señala 71,741,508 acciones con poder de voto exclusivo y 790,804 con poder de voto compartido. También informa 81,264,020 acciones con poder dispositivo exclusivo y 625,305 con poder dispositive compartido. JPMorgan certificó que los valores fueron adquiridos y se mantienen en el curso normal de los negocios y no para cambiar o influir en el control.

브리스톨-마이어스 스퀴브(BMY): 소유 현황 업데이트. JPMorgan Chase & Co.은 실질적 소유권 81,890,781주를 보고한 수정 Schedule 13G를 제출했으며, 이는 BMY의 보통주 4.0%에 해당합니다. 2025-09-30.

신고서는 단독 의결권이 있는 71,741,508주와 공동 의결권이 있는 790,804주를 목록에 올립니다. 또한 81,264,020주는 단독 처분 권한, 625,305주는 공동 처분 권한을 갖는 것으로 보고합니다. JPMorgan은 증권이 정상적인 영업상의 취득으로 이루어졌으며 지배권을 변경하거나 영향 주려는 목적이 아님을 증명했습니다.

Bristol-Myers Squibb (BMY) : Mise à jour de la propriété. JPMorgan Chase & Co. a déposé un Schedule 13G modifié annonçant une propriété bénéficiaire de 81 890 781 actions, représentant 4,0% des actions ordinaires de BMY au 30/09/2025.

Le dossier indique 71 741 508 actions avec pouvoir de vote exclusif et 790 804 avec pouvoir de vote partagé. Il indique également 81 264 020 actions avec pouvoir discrétionnaire exclusif et 625 305 avec pouvoir discrétionnaire partagé. JPMorgan a certifié que les titres ont été acquis et détenus dans le cadre normal des activités et non pour modifier ou influencer le contrôle.

Bristol-Myers Squibb (BMY): Eigentumsaktualisierung. JPMorgan Chase & Co. hat einen geänderten Schedule 13G eingereicht, der das wirtschaftliche Eigentum an 81.890.781 Aktien meldet, was 4,0% des BMY-Stammkapitals entspricht, zum 30.09.2025.

Die Einreichung listet 71.741.508 Aktien mit Alleinigem Stimmrecht und 790.804 mit gemeinsamem Stimmrecht. Sie meldet auch 81.264.020 Aktien mit Alleinem Verfügungsmacht und 625.305 mit gemeinsamer Verfügungsmacht. JPMorgan bestätigte, dass die Wertpapiere im normalen Geschäftsverlauf erworben und gehalten wurden und nicht dazu dienen, die Kontrolle zu ändern oder zu beeinflussen.

بريستل-مايرز سكويب (BMY): تحديث الملكية. قدمت جي بي مورجان تشيس وشركاه Schedule 13G معدلاً يفيد بالملكية المفيدة لـ81,890,781 سهماً، وهو يمثل 4.0% من أسهم BMY العادية حتى 30/09/2025.

تسرد الإيداع 71,741,508 سهماً بسلطة التصويت الحصرية و790,804 مع سلطة التصويت المشتركة. كما تقرر 81,264,020 سهماً بسلطة التصرف الحصري و625,305 مع سلطة التصرف المشتركة. وذكرت JPMorgan أن الأوراق المالية مكتسبة ومملوكة في إطار الأعمال الاعتيادية وليست بغرض تغيير أو التأثير في السيطرة.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G



JPMORGAN CHASE & CO.
Signature:Rachel Tsvaygoft
Name/Title:Vice President
Date:10/31/2025

FAQ

What did JPMorgan disclose about BMY (Bristol-Myers Squibb) in this 13G/A?

JPMorgan reported beneficial ownership of 81,890,781 BMY shares, equal to 4.0% of the class as of 09/30/2025.

How much voting power did JPMorgan report over BMY shares?

They listed 71,741,508 shares with sole voting power and 790,804 with shared voting power.

What dispositive power did JPMorgan report over its BMY holdings?

They reported 81,264,020 shares with sole dispositive power and 625,305 with shared dispositive power.

Is JPMorgan’s BMY position passive or for influencing control?

The certification states the position was acquired and is held in the ordinary course and not to change or influence control.

What is the event date referenced in the BMY 13G/A?

The date of the event requiring the filing is 09/30/2025.

Who signed the 13G/A filing and when?

It was signed by Rachel Tsvaygoft, Vice President, dated 10/31/2025.
Bristol-Myers Squibb Co

NYSE:BMY

BMY Rankings

BMY Latest News

BMY Latest SEC Filings

BMY Stock Data

92.86B
2.03B
0.07%
82.82%
1.53%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States
PRINCETON